Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

Inhaled corticosteroids deserve further consideration for lung cancer chemoprevention

Among a group of mostly older male veterans suffering from chronic obstructive pulmonary disease (COPD), an illness that offers a greater susceptibility to lung cancer, researchers found that regular use of high dose inhaled corticosteroids (ICS) lowered the risk of developing lung cancer.

4 Apr 2007

Tykerb (lapatinib) - new anti-cancer treatment approved

The Food and Drug Administration (FDA) has approved Tykerb (lapatinib), a new targeted anti-cancer treatment, to be used in combination with capectabine (Xeloda), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive (tumors that exhibit HER2 protein).

14 Mar 2007

Experimental drug provides powerful therapy against acute myeloid leukemia

Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.

19 Nov 2006

Cocktail of two drugs heals damaged hearts

A cocktail of drugs has been found in trials with animals to heal damaged heart muscle.

10 Oct 2006

Gleevec may cause heart problems

Gleevec, the wildly successful poster-child of a new generation of cancer drugs aimed at specific targets in the cancer cell, can be dangerous to the heart.

24 Jul 2006

Nexavar approved in Europe for treatment of advanced kidney cancer

Bayer Pharmaceuticals Corporation and Onyx Pharmaceuticals, Inc have announced that the European Commission has granted marketing authorization to Nexavar (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma.

24 Jul 2006

Dasatinib offers new options for leukemia patients

Dasatinib, an experimental drug under development by Bristol-Myers Squibb, reverses the signs and symptoms of patients whose chronic myeloid leukemia has failed to respond to Gleevec, which is considered the standard of treatment for the disorder.

14 Jun 2006

New data show Enzastaurin's activity across multiple cancer cell lines

Eli Lilly and Company's enzastaurin, an investigational, multi-targeted therapy that is currently the focus of two global Phase III clinical trials, one for the treatment of glioblastoma and one in non-Hodgkin's lymphoma

5 Jun 2006

Novel animal model of lung adenocarcinoma

Drs. Katerina Politi, Harold Varmus and colleagues at the Memorial Sloan Kettering Cancer Center in New York have developed a novel animal model of lung adenocarcinoma that will be of great use in testing the efficacy of targeted therapies against human lung cancer.

17 May 2006

New compound shows unique potency against cancer cell proliferation

By determining how a class of compounds blocks signaling in cells, University of California, San Francisco (UCSF) scientists have identified what is perhaps the most potent drug candidate yet against a highly lethal kind of brain tumor.

16 May 2006

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma

Scientists have identified a new molecule that inhibits proliferation of a broad range of lethal malignant glioma cells in vitro and in vivo.

16 May 2006

Therapy for metastatic renal cell carcinoma remains inadequate

The recent FDA approvals of the tyrosine kinase inhibitors sorafenib and sunitinib based on their activity in metastatic renal cell carcinoma have excited the medical oncology community

9 Mar 2006

Lilly launches phase III trial of Enzastaurin

One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today.

9 Mar 2006

Novel mouse model of medulloblastoma

A collaboration of researchers, led by Dr. Martine Roussel of St. Jude Children's Research Hospital, has developed a novel mouse model of medulloblastoma -- the most prevalent malignant pediatric brain tumor -- that the researchers hope will more accurately represent the genetic changes involved in human brain tumor development.

30 Oct 2005

Australian researchers determine structure of JAK2 kinase, huge implications for development of new cancer drugs

Researchers from Monash's Department of Biochemistry and Molecular Biology have determined the structure of the protein JAK2 kinase, a discovery with huge implications for the design and development of new cancer drugs.

25 Oct 2005

Raf Kinase Inhibitor Protein plays a role in controlling the active movement of cells

University of Illinois at Chicago researchers report that a protein that regulates key signaling pathways in cells also plays a role in controlling the active movement or migration of cells. The finding may suggest new pharmaceutical therapies for treating a variety of diseases, including cancer.

26 Sep 2005

Tarceva should be tested as front-line therapy for older lung cancer patients

The tyrosine kinase inhibitor erlotinib (Tarceva) showed encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer (NSCLC), reports a team led by investigators from Dana-Farber Cancer Institute in Boston.

19 Sep 2005

Study examines biomarkers for response to erlotinib in glioma

Researchers have found two biomarkers that, in patients with a malignant type of brain tumor called glioblastoma multiforme, were associated with response to the cancer drug erlotinib (Tarceva).

14 Jun 2005

Triple approach is promising against cancer cells

A trimodal treatment strategy combining chemotherapy, radiation therapy, and a protein kinase inhibitor is much more effective against cancer cells than any combination of only two treatment methods.

1 Jun 2005

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Recent studies of a new anticancer drug show continued response for patients with late-stage kidney cancer. Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), reported a response rate of 40 percent in patients with metastatic (advanced) renal cell (kidney) cancer who received SU11248 in second-line therapy.

15 May 2005